IP Library Granted Patent US 7,524,927
Granted Patent B2
US 7,524,927 · App. 10/767,648 · Granted Apr 28, 2009

Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions

Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,927
App. No.
10/767,648
Granted
Apr 28, 2009
Kind
B2
Abstract

The present invention relates to replication competent variants of mammalian immunodeficiency virus comprising mutations and/or deletions of the V3 hypervariable loop and compensatory mutations, as well as methods for producing such variants. The invention also relates to V3-loop deletion mammalian immunodeficiency virus mutants that have compensatory mutations, deletions of the V1/V2 loops, or both. The invention further relates to isolated Env, gp120 polypeptides, and gp41 polypeptides comprising novel mutations useful in conjunction with, or separate from, a virus of the invention, as well as nucleic acids encoding the same.

Claims (7)

1. An isolated nucleic acid encoding a mammalian immunodeficiency virus glycoprotein (gp) 120 polypeptide, wherein said gp120 polypeptide comprises a deletion of hypervariable loop 3 (V3), and further comprises a compensatory mutation, wherein said compensatory mutation is an amino acid substitution from threonine to alanine at amino acid residue number 391, wherein the amino acid residue number of said compensatory mutation is relative to the amino acid sequence of parental HIV-2/vcp gp120 as provided in SEQ ID NO:5.

2. The isolated nucleic acid of claim 1 , wherein said mammalian immunodeficiency virus is human immunodeficiency virus type 2 (HIV-2).

3. The isolated nucleic acid of claim 2 , wherein said deletion of V3 is a deletion of from about amino acid residue number 303 to amino acid residue number 324 (ΔV3(6,6)) relative to the amino acid sequence of HIV-2/vcp gp120 as provided in SEQ ID NO:5.

4. The isolated nucleic acid of claim 3 , wherein said V3 deletion is ΔV3(6,6).

5. The isolated nucleic acid of claim 1 , wherein the amino acid sequence of said gp120 polypeptide encoded by said nucleic acid is the amino acid sequence of SEQ ID NO:11.

6. An isolated nucleic acid encoding a mammalian immunodeficiency virus glycoprotein (gp) 120 polypeptide wherein said gp120 polypeptide comprises a deletion of hypervariable loop 3 (V3) and further comprises a compensatory mutation wherein the nucleic acid sequence of said nucleic acid is the sequence of SEQ ID NO:8.

7. The isolated nucleic acid of claim 6 , wherein said deletion is from about amino acid residue number 303 to amino acid residue number 324 (ΔV3(6,6)), relative to the amino acid sequence of HIV-2/vcp gp120 as provided in SEQ ID NO:5.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 28, 2011
From: PENNSYLVANIA, UNIVERSITY OF
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025711/0681 →
CONFIRMATORY LICENSE Recorded Jan 25, 2011
From: PENNSYLVANIA, UNIVERSITY OF
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025689/0849 →
CONFIRMATORY LICENSE Recorded Sep 26, 2008
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021596/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2006
From: HOXIE, JAMES A; LIN, GEORGE
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 017322/0455 →
Continuity (2)
Provisional Application 6044336400 · Jan 29, 2003
Related Publication 20050064392A1 · Mar 24, 2005